Intercell Expands to Scotland
Vienna - Austrian biotech company Intercell AG acquired a multi-purpose biologics manufacturing plant in Living-ston, Scotland. Intercell will use the manufacturing capacity for its late-stage Japanese encephalitis vaccine and for its vaccine pipeline resulting from its bacterial antigen identification research and development programmes. Alexander von Gabain, Inter-cell's CEO: “Scotland's vibrant science community and excellent reputation for the quality of its research and production were a big incentives for Intercell to expand operations to Edinburgh.”
The 30,000 square foot, state-of-the-art GMP facility was formerly owned by Excell Biotech, and has only recently become fully operational. The facility is designed according to the most up-to-date international standards for biologics product manufacturing. Through the acquisition, Intercell will also access the skills of a team of highly experienced staff with a broad expertise in process development, manufacturing and quality management of viral and recombinant protein products.
“This strategically very important acquisition will allow Intercell to fully control the clinical and future commercial manufacturing of our Japanese encephalitis vaccine, which is planned to enter phase III clinical trials in early 2005. Furthermore we will have the capabilities to develop and produce in-house any future recombinant bacterial vaccines resulting from our innovative Antigen Identification Programme“, commented COO Gerd Zettlmeissl.
Intercell has been supported by Scottish Development International and Scottish Enterprise Edinburgh and Lothian.